HOXC-AS1: A Key Biomarker for Prognosis and Immunotherapy in Lung Adenocarcinoma
The research indicated a strong association between higher levels of HOXC-AS1 and negative outcomes in LUAD, such as reduced survival rates and the presence of immune cell infiltration. HOXC-AS1 could potentially be utilized as a biomarker to anticipate patient prognosis and their likelihood of responding to immunotherapies in LUAD.
Authors
- Haiyin Ye
- Qiu Huang (ORCID: https://orcid.org/0009-0008-0296-159X)
- Boyun Deng (ORCID: https://orcid.org/0000-0002-6801-1377)
- Dongbing Li (ORCID: https://orcid.org/0000-0002-5227-9643)
- Xiao Yang
- Yutao Pang
Institutions
- Guangdong Medical College (CN)
Publication Details
- Journal
- Current Computer - Aided Drug Design
- Published
- 2025-03-06
- DOI
- https://doi.org/10.2174/0115734099353461250219072304
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00